Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, introduced today the DR Market Model -- a new offering that enables companies to quickly develop insight into the commercial potential of their compounds. The DR Market Model, a customizable combination of Decision Resources' products and consulting services, is specifically designed to enable small companies to better understand the market for their compounds and estimate their market penetration and peak year dollar market potential.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"The goal of the program is to combine Decision Resources' unique data and knowledge with a biotech's proprietary expertise about their compound," said Joe Walsh, VP of Business Development at Decision Resources.

"It's all about winning and this combination of products and services will enable smaller companies to develop information and insight usually reserved for larger companies," added Jim McDermott, VP of Consulting at Decision Resources.

  Program Components Include:   One DR Pharmacor report coupled with an Interactive Forecast Tool 

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development by disease.

Interactive Forecast Tool is a highly interactive modeling capability, built on Decision Resources in-house knowledge and data bases, that is easily modified to provide alternate scenarios for a product's potential

Up to one week of consulting from Decision Resources' in-house experts

Decision Resources' in-house staff brings their broad expertise and the new Market Model framework to assist biotechnology companies in identifying the potential for their product, understanding the dynamics of the selected therapeutic/disease market and recommending key action steps required to reaching that potential.

"Decision Resources has been a clear leader in providing expert analysis to the biopharmaceutical and investment communities for over 25 years," said Sarah Fuller, President of Decision Resources. "We feel our research and in- house expertise can also be invaluable to the biotechnology sector. That's why we created the DR Market Model to provide these companies with a strategic cost-effective platform for new product planning."

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic advisory services for 25 years, assessing international pharmaceutical and health care industry trends and events. Visit Decision Resources at http://www.dresources.com/.

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563    emarshall@dresources.com 

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X29456356

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
emarshall@dresources.com

Market for Deep Vein Thrombosis/Pulmonary Embolism is Poised for Significant Growth, According to a New Decision Resources' Study

View Now